Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Withdrawn
Janssen Scientific Affairs, LLC
Phase 2/Phase 3
2016-05-01
This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™,
DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV
viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be
effective in maintaining virologic suppression at 48 weeks of treatment.
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Withdrawn
University of Colorado, Denver
Phase 2/Phase 3
2016-05-01
This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™,
DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV
viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be
effective in maintaining virologic suppression at 48 weeks of treatment.
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Withdrawn
Stanford University
Phase 2/Phase 3
2016-05-01
This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™,
DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV
viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be
effective in maintaining virologic suppression at 48 weeks of treatment.
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres
Completed
Gilead Sciences
Phase 3
2015-11-20
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose
combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus
continuing on a regimen consisting of boosted atazanavir (ATV) or darunavir (DRV) plus either
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) in
HIV-1 infected adults who are virologically suppressed.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
